Sjögren's SyndromePhase 2SSNCT04129164
A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome
A Phase 2 study testing VIB4920 in people with Sjögren's Syndrome, run by Amgen at 62 sites in 12 countries.
Trial summary
The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS). Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Sjögren's Syndrome
- What is being tested?
- VIB4920
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 183 participants
- Where
- 62 sitesin 12 countries
- Study dates
- 9 Dec 2019to 10 Mar 2023
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosed with SS by meeting the 2016 American College of Rheumatology (ACR)/EULAR Classification Criteria.
- Residual salivary gland function as defined by whole stimulated salivary flow > 0.1 mL/min (only for Population 2).
- Have an ESSDAI score of >= 5 at screening; (not including the peripheral nervous system, central nervous system, and pulmonary domains) (only for Population 1).
- Have an ESSPRI score of >= 5 at screening (only for Population 2).
- Have an ESSDAI score of < 5 at screening (only for Population 2).
- Positive for either anti-Ro autoantibodies or rheumatoid factor, or both at screening.
- Male and female participants who agree to follow protocol defined contraceptive methods.
- No active or untreated latent tuberculosis (TB).
Who cannot join
- Medical history of confirmed deep venous thrombosis or arterial thromboembolism within 2 years of signing the informed consent form (ICF).
- Risk factors for venous thromboembolism or arterial thrombosis, prothrombotic status.
- Concomitant polymyositis or dermatomyositis or systemic sclerosis.
- Active malignancy or history of malignancy, except in situ carcinoma of the cervix and cutaneous basal cell carcinoma.
- Hepatitis B, hepatitis C, or human immunodeficiency virus infection.
- More than one episode of herpes zoster and/or an opportunistic infection in the last 12 months.
Show all 15Show fewer
- Active viral, bacterial, or other infections or history of more than 2 infections requiring intravenous antibiotics within 12 months prior to signing the ICF.
- Participants with corona virus disease 2019 (COVID-19) infection or who, in the judgment of the investigator, are at unacceptable risk of COVID-19 or its complications.
- A documented positive severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) test within 2 weeks prior to randomization.
- Received live (attenuated) vaccine within the 4 weeks prior to ICF signature.
- Treated with any biologic B-cell-depleting therapy within 12 months or other B-cell targeting therapy < 3 months before randomization.
- Injectable corticosteroids (including intraarticular) or treatment with > 10 mg/day dose oral prednisone or equivalent within 6 weeks prior to randomization (only for Population 1).
- Treated with systemic corticosteroids for indications other than SS, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE) for more than a total of 2 weeks within 24 weeks prior to screening visit (only for Population 1).
- Received previous treatment with anti-CD40L compounds at any time before screening.
- Pregnant or lactating or planning to get pregnant during the duration of the study.
Trial locations and contacts
62 sites in 12 countries.
62 sites in 12 countries
United States16 sites
Research Site
Baltimore, Maryland, 21224
Research Site
Boston, Massachusetts, 02111
Research Site
Charlotte, North Carolina, 28204
Research site
Dallas, Texas, 75231
Research site
Duncansville, Pennsylvania, 16635
Research Site
Durham, North Carolina, 27710
Research Site
Fullerton, California, 92835
Research Site
Houston, Texas, 77084
Research Site
Houston, Texas, 77089
Research Site
Kansas City, Kansas, 66160
Research Site
Lawrenceville, Georgia, 30046
Research Site
Memphis, Tennessee, 38119
Research Site
Salisbury, North Carolina, 28144
Research site
Upland, California, 91786
Research Site
Wheaton, Maryland, 20902
Research Site
Wilmington, North Carolina, 28401
Poland9 sites
Research Site
Elblag, Elblag, 82-300
Research Site
Krakow, 30-363
Research Site
Lublin, 20-412
Research Site
Poznan, 60-693
Research Site
Siedlce, 08-110
Research Site
Szczecin, 71-252
Research Site
Warsaw, 02-637
Research Site
Warsaw, 02-691
Research Site
Wroclaw, 02-637
India7 sites
Research Site
Ahmedabad, Gujarat, 380015
Research Site
Bangalore, Karnataka, 560010
Research Site
Bhubaneswar, Odisha, 751005
Research Site
Chennai, Tamil Nadu, 600004
Research Site
Pune, Maharshtra, 411001
Research Site
Pune, Maharshtra, 411013
Research Site
Secunderabad, Andhra Pradesh, 5000003
Italy6 sites
Research Site
Brescia, Province Of Brescia, 25123
Research Site
Milan, Lambardia, 20122
Research Site
Perugia, Umbria, 06129
Research Site
Pisa, 56126
Research Site
Rome, Lazio, 00161
Research Site
Udine, 33100
France5 sites
Research Site
Bordeaux
Research Site
Brest
Research Site
Grenoble
Research Site
Paris
Research Site
Strasbourg
Mexico4 sites
Research Site
Guadalajara, Jalisco, 44650
Research Site
Guadalajara, Jalisco, 44690
Research Site
Mexico City, 06700
Research Site
Saltillo, Coahuila, 25000
South Korea4 sites
Research Site
Incheon, Republic of Korea, 21565
Research Site
Incheon, Republic of Korea, 22332
Research Site
Seoul, Republic of Korea, 06591
Research Site
Suwon, Gyeonggi-do, 16499
Hungary3 sites
Research Site
Budapest, 1097
Research Site
Debrecen, 4032
Research Site
Gyula, 5700
Peru3 sites
Research Site
Lima, San Martin de Porres, 31
Research Site
Lima, 1
Research Site
Lima, 33
United Kingdom2 sites
Research Site
Newcastle upon Tyne, NE1 4LP
Research Site
Truro, TR13LJ
Argentina1 site
Research Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, C1114AAH
About this study
Official title: A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects With Sjögren's Syndrome (SS)
The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS).
Read the detailed description
The study will enrol 2 SS populations: Population 1 will include participants with moderate to high systemic disease activity defined by European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) >= 5; Population 2 will include participants with moderate to severe subjective symptoms defined by EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) score >= 5 and residual stimulated salivary flow but with mild systemic disease activity defined by ESSDAI score < 5. This study will include 3 periods: screening (4 weeks), treatment period (40 Weeks) and follow-up period (12 weeks). In the treatment period, participants from each of the populations will be randomized at 1:1 ratio to receive intravenous (IV) dose of VIB4920 or placebo (Stage I). After completion of Stage I, participants randomized to VIB4920 in Stage I will receive placebo and participants randomized to placebo in Stage I will receive VIB4920 (Stage II). Participants who had study drug discontinuation will not be eligible for treatment during Stage II. All participants will be followed for at least 12 weeks after their last dose of study drug administration.
Study acquired from Horizon in 2024.
- Conditions
- Sjögren's Syndrome
- Being tested
- VIB4920, Placebo
- Keywords
- Sjögren's Syndrome, SS, VIB4920, MEDI4920
- Medical subject headings
- Sjogren's Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VIB4920Drug
Also called Dazodalibep
Intravenous Dose 1.
PlaceboDrug
Intravenous dose matched to VIB4920.
| Study group | Role | What they receive |
|---|---|---|
| VIB4920 Dose 1 in Population 1 | Experimental | Participants in population 1 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II. Receives: Drug: VIB4920; Drug: Placebo |
| Placebo in Population 1 | Placebo comparator | Participants in population 1 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II. Receives: Drug: VIB4920; Drug: Placebo |
| VIB4920 Dose 1 in Population 2 | Experimental | Participants in population 2 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II. Receives: Drug: VIB4920; Drug: Placebo |
| Placebo in Population 2 | Placebo comparator | Participants in population 2 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II. Receives: Drug: VIB4920; Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Population 1: Change From Baseline in ESSDAI at Day 169
The ESSDAI is a systemic disease activity index for SS, assessing 12 domains (Constitutional, Salivary Glands, Lungs, Kidneys, Musculoskeletal, Peripheral Nervous System, Central Nervous System, Vascular, Gastrointestinal, Hematological, Ocular, and Extraglandular Manifestations). Each domain is graded for activity (0 = no activity to 3 = high activity) and weighted (1 for Biological to 6 for Muscular) based on its clinical significance, with the final score calculated as the sum of all weighted domain scores. The theoretical range is 0 to 123, with disease activity categorized as low (<5), moderate (5-13), and high (≥14). A positive change form baseline represents an increase in symptoms.
Measured: Baseline and Day 169
Population 2: Change From Baseline in ESSPRI at Day 169
The ESSPRI is a self-assessment tool for evaluating symptoms of dryness, fatigue, and pain (articular and/or muscular) in SS. Participants rate each of the three domains on a 0-10 numerical scale (0 = no; 10 maximal imaginable severity). All domains are equally weighted, and the total score is the mean of the three domain scores. The maximum total score for the ESSPRI assessment is 10. A positive change form baseline represents an increase in symptoms.
Measured: Baseline and Day 169
Secondary outcomes (8)
Population 1: Change From Baseline in ESSPRI at Day 169
The ESSPRI is a self-assessment tool for evaluating symptoms of dryness, fatigue, and pain (articular and/or muscular) in SS. Participants rate each of the three domains on a 0-10 numerical scale (0 = no; 10 maximal imaginable severity). All domains are equally weighted, and the total score is the mean of the three domain scores. The maximum total score for the ESSPRI assessment is 10. A positive change from baseline represents an increase in symptoms.
Measured: Baseline and Day 169
Population 1: Number of Participants Who Achieved ESSDAI[3] and ESSDAI[4] Response at Day 169
The ESSDAI is a systemic disease activity index for primary Sjögren's syndrome, assessing 12 domains (e.g., cutaneous, renal, CNS, and biological). Each domain is graded for activity (0 = no activity to 3 = high activity) and weighted (1 for Biological to 6 for Muscular) based on its clinical significance, with the final score calculated as the sum of all weighted domain scores. The theoretical range is 0 to 123, with disease activity categorized as low (<5), moderate (5-13), and high (≥14). A positive change from baseline represents an increase in symptoms.
ESSEDAI[3] and [4] responses were defined as a decrease of at least 3 or 4 points respectively in the ESSDAI score from the baseline value, measured at Day 169.
Measured: Day 169
Change From Baseline in The Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Day 169
The FACIT-Fatigue is a 13-item patient-reported questionnaire designed to assess the impact of fatigue on quality of life (QoL). Responses are scored from 0 (Not at all) to 4 (Very Much). The total score is the sum of all responses, ranging from 0 to 52, with higher scores indicating better QoL. A positive change from baseline represents an increase in QoL.
Measured: Baseline and Day 169
Change From Baseline in Ocular Surface Disease Index (OSDI) at Day 169
The OSDI is a validated tool for assessing vision-related function and dry eye disease severity (normal, mild, moderate, severe). It consists of 12 questions, with responses ranging from 0 (None of the time) to 4 (All of the time). Scores range from 0 to 100, as it is calculated by transforming the raw responses from the 12 questions into a standardized 0-100 scale, with higher scores indicating greater disability. A positive change from baseline indicates a worsening vision-related function.
Measured: Baseline and Day 169
Patient Global Impression of Severity (PGIS) Score at Day 169
The PGIS is a single-item measure that captures a patient's perception of overall symptom severity over the past week, using a 5-point categorical response scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe), with higher scores indicating greater symptom severity. Positive change from baseline values indicate worsening of symptoms severity.
Measured: Baseline and Day 169
Population 2: Number of Participants Who Achieved ESSPRI Response at Day 169
The ESSPRI is a self-assessment tool for evaluating symptoms of dryness, fatigue, and pain (articular and/or muscular) in SS. Participants rate each of the three domains on a 0-10 numerical scale (0 = no; 10 maximal imaginable severity). All domains are equally weighted, and the total score is the mean of the three domain scores. The maximum total score for the ESSPRI assessment is 10. A positive change form baseline represents an increase in symptoms. Participants achieving an ESSPRI response were defined as at least a 1 point or 15% reduction from baseline in ESSPRI score at Day 169 without premature discontinuation from the study and without receiving rescue medications.
Measured: Day 169
Number of Participants Who Experience Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) referred to any untoward medical occurrence in a clinical study participant, regardless of a causal relationship with the study treatment. TEAEs included any event occurring after the participant received the study treatment. Clinically significant changes in vital signs, electrocardiograms, and laboratory tests recorded after treatment administration were documented as TEAEs. Serious TEAEs (SAEs) were untoward medical occurrences after the first dose, irrespective of a causal link to the study treatment, that led to death, were life-threatening, required hospitalization or its prolongation, caused significant disability, resulted in congenital anomalies, or were considered other medically important events. AEs were graded (Grade 3: severe; Grade 4: life-threatening; Grade 5: death) using the Common Terminology Criteria for Adverse Events (CTCAE).
Measured: Up to approximately 365 days
Serum Concentration of VIB4920
Blood samples were collected at the specified time points.
Measured: Day 1 pre-dose, Day 1 post-dose, Day 15, Day 29, Day 57, Day 85, Day 113, Day 141 pre-dose, Day 141 post-dose, Day 169 pre-dose, Day 169 post-dose, Day 197, Day 225, Day 253, Day 281, Day 309, Day 365
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Oct 2019
- Study start9 Dec 2019
- Primary completion1 Sep 2022
- Study completion10 Mar 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Sjögren's SyndromeStudies of the same condition, open and under way.
- More trials run by AmgenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 183 participants (actual)
Sponsor and investigators
- Lead sponsor
- Amgen
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- MD, Study director, Amgen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04129164
- Sponsor's protocol ID
- VIB4920.P2.S2
- Other IDs
- 2019-002713-19, 2019
- Acronym
- SS
- Status last verified
- Apr 2025
- First submitted
- 2 Oct 2019
- Last updated
- 30 Apr 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
St Clair EW, Baer AN, Ng WF, Noaiseh G, Baldini C, Tarrant TK, Papas A, Devauchelle-Pensec V, Wang L, Xu W, Pham TH, Sikora K, Rees WA, Alevizos I. CD40 ligand antagonist dazodalibep in Sjogren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial. Nat Med. 2024 Jun;30(6):1583-1592. doi: 10.1038/s41591-024-03009-3. Epub 2024 Jun 5.
PubMed 38839899
Study at a glance
From the registry record, last updated by the sponsor on 30 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects With Sjögren's Syndrome (SS)
- ClinicalTrials.gov ID
- NCT04129164
- Acronym / sponsor ID
- SS / VIB4920.P2.S2
- Conditions
- Sjögren's Syndrome
- Keywords
- Sjögren's Syndrome, SS, VIB4920, MEDI4920
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 183 participants (actual)
- Lead sponsor
- AmgenIndustry (pharma, biotech, devices)
- Study start
- 9 Dec 2019 (actual)
- Primary completion
- 1 Sep 2022 (actual)
- Study completion
- 10 Mar 2023 (actual)
- First posted
- 16 Oct 2019 (actual)
- Results
- Posted 30 Apr 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS).
Detailed description
The study will enrol 2 SS populations: Population 1 will include participants with moderate to high systemic disease activity defined by European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) >= 5; Population 2 will include participants with moderate to severe subjective symptoms defined by EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) score >= 5 and residual stimulated salivary flow but with mild systemic disease activity defined by ESSDAI score < 5. This study will include 3 periods: screening (4 weeks), treatment period (40 Weeks) and follow-up period (12 weeks). In the treatment period, participants from each of the populations will be randomized at 1:1 ratio to receive intravenous (IV) dose of VIB4920 or placebo (Stage I). After completion of Stage I, participants randomized to VIB4920 in Stage I will receive placebo and participants randomized to placebo in Stage I will receive VIB4920 (Stage II). Participants who had study drug discontinuation will not be eligible for treatment during Stage II. All participants will be followed for at least 12 weeks after their last dose of study drug administration.
Study acquired from Horizon in 2024.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| VIB4920 Dose 1 in Population 1 | Experimental | Drug: VIB4920, Drug: PlaceboParticipants in population 1 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II. |
| Placebo in Population 1 | Placebo comparator | Drug: VIB4920, Drug: PlaceboParticipants in population 1 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II. |
| VIB4920 Dose 1 in Population 2 | Experimental | Drug: VIB4920, Drug: PlaceboParticipants in population 2 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II. |
| Placebo in Population 2 | Placebo comparator | Drug: VIB4920, Drug: PlaceboParticipants in population 2 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Diagnosed with SS by meeting the 2016 American College of Rheumatology (ACR)/EULAR Classification Criteria.
- Residual salivary gland function as defined by whole stimulated salivary flow > 0.1 mL/min (only for Population 2).
- Have an ESSDAI score of >= 5 at screening; (not including the peripheral nervous system, central nervous system, and pulmonary domains) (only for Population 1).
- Have an ESSPRI score of >= 5 at screening (only for Population 2).
- Have an ESSDAI score of < 5 at screening (only for Population 2).
Key exclusion criteria (15 listed)
- Medical history of confirmed deep venous thrombosis or arterial thromboembolism within 2 years of signing the informed consent form (ICF).
- Risk factors for venous thromboembolism or arterial thrombosis, prothrombotic status.
- Concomitant polymyositis or dermatomyositis or systemic sclerosis.
- Active malignancy or history of malignancy, except in situ carcinoma of the cervix and cutaneous basal cell carcinoma.
- Hepatitis B, hepatitis C, or human immunodeficiency virus infection.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VIB4920Also: DazodalibepIntravenous Dose 1. | Drug | Placebo in Population 1, Placebo in Population 2, VIB4920 Dose 1 in Population 1, VIB4920 Dose 1 in Population 2 |
| PlaceboIntravenous dose matched to VIB4920. | Drug | Placebo in Population 1, Placebo in Population 2, VIB4920 Dose 1 in Population 1, VIB4920 Dose 1 in Population 2 |
Primary outcome
Population 1: Change From Baseline in ESSDAI at Day 169
Time frame: Baseline and Day 169
The ESSDAI is a systemic disease activity index for SS, assessing 12 domains (Constitutional, Salivary Glands, Lungs, Kidneys, Musculoskeletal, Peripheral Nervous System, Central Nervous System, Vascular, Gastrointestinal, Hematological, Ocular, and Extraglandular Manifestations). Each domain is graded for activity (0 = no activity to 3 = high activity) and weighted (1 for Biological to 6 for Muscular) based on its clinical significance, with the final score calculated as the sum of all weighted domain scores. The theoretical range is 0 to 123, with disease activity categorized as low (<5), moderate (5-13), and high (≥14). A positive change form baseline represents an increase in symptoms.
Population 2: Change From Baseline in ESSPRI at Day 169
Time frame: Baseline and Day 169
The ESSPRI is a self-assessment tool for evaluating symptoms of dryness, fatigue, and pain (articular and/or muscular) in SS. Participants rate each of the three domains on a 0-10 numerical scale (0 = no; 10 maximal imaginable severity). All domains are equally weighted, and the total score is the mean of the three domain scores. The maximum total score for the ESSPRI assessment is 10. A positive change form baseline represents an increase in symptoms.
8 secondary outcomes
Population 1: Change From Baseline in ESSPRI at Day 169
Time frame: Baseline and Day 169
Population 1: Number of Participants Who Achieved ESSDAI[3] and ESSDAI[4] Response at Day 169
Time frame: Day 169
Change From Baseline in The Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Day 169
Time frame: Baseline and Day 169
Change From Baseline in Ocular Surface Disease Index (OSDI) at Day 169
Time frame: Baseline and Day 169
Patient Global Impression of Severity (PGIS) Score at Day 169
Time frame: Baseline and Day 169
Population 2: Number of Participants Who Achieved ESSPRI Response at Day 169
Time frame: Day 169
Number of Participants Who Experience Treatment-emergent Adverse Events (TEAEs)
Time frame: Up to approximately 365 days
Serum Concentration of VIB4920
Time frame: Day 1 pre-dose, Day 1 post-dose, Day 15, Day 29, Day 57, Day 85, Day 113, Day 141 pre-dose, Day 141 post-dose, Day 169 pre-dose, Day 169 post-dose, Day 197, Day 225, Day 253, Day 281, Day 309, Day 365
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Apr 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 38839899St Clair EW, Baer AN, Ng WF, Noaiseh G, Baldini C, Tarrant TK, Papas A, Devauchelle-Pensec V, Wang L, Xu W, Pham TH, Sikora K, Rees WA, Alevizos I. CD40 ligand antagonist dazodalibep in Sjogren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial. Nat Med. 2024 Jun;30(6):1583-1592. doi: 10.1038/s41591-024-03009-3. Epub 2024 Jun 5.
- AmgenTrials clinical trials websiteLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Sjögren's Syndrome
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Recruiting
Evaluation of the Prevalence, and Immunological Characteristics of Small Fiber Neuropathy in Patients With Primary Sjögren's Syndrome
Sjögren's Syndrome, Small Fiber Neuropathy
Not yet recruitingPhase 1
A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases
Systemic Lupus Erythematosus, Rheumatoid Arthritis (RA)
RecruitingPhase 2
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
Sjögren's Disease
RecruitingPhase 2
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE
Sjögren's Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
MD study director
Amgen
62 sites in 12 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing VIB4920 in people with Sjögren's Syndrome, run by Amgen at 62 sites in 12 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 62 sites in United States, Poland, India, Italy, France and 7 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 30 Apr 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Population 1: Change From Baseline in ESSDAI at Day 169 (time frame: Baseline and Day 169). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04129164, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Apr 2025.